Reaktionsgleichung
[F:1][C:2]1[CH:3]=[C:4]([C:9]2[C:17]3[C:12](=[CH:13][C:14]([OH:18])=[CH:15][CH:16]=3)[C:11](=[O:19])[C:10]=2[C:20]2[CH:21]=[N:22][CH:23]=[CH:24][CH:25]=2)[CH:5]=[C:6]([F:8])[CH:7]=1.BrC1C(=O)C2C(C=1C1C=CC=CC=1)=CC=C(O)C=2.[N:44]1([CH2:50][CH2:51]O)[CH2:49][CH2:48][CH2:47][CH2:46][CH2:45]1>>[F:8][C:6]1[CH:5]=[C:4]([C:9]2[C:17]3[C:12](=[CH:13][C:14]([O:18][CH2:51][CH2:50][N:44]4[CH2:49][CH2:48][CH2:47][CH2:46][CH2:45]4)=[CH:15][CH:16]=3)[C:11](=[O:19])[C:10]=2[C:20]2[CH:21]=[N:22][CH:23]=[CH:24][CH:25]=2)[CH:3]=[C:2]([F:1])[CH:7]=1Komponenten
4
Versuchsvorschrift
The procedure of Step 6 of Example 1 was repeated except for using 3-(3,5-difluorophenyl)-6-hydroxy-2-(pyridin-3-yl)-1H-inden-1-one obtained in Step 1 of Example 61 as a starting material instead of 2-bromo-6-hydroxy-3-phenyl-1H-inden-1-one, 2-(piperidin-1-yl)ethanol instead of 4-(2-hydroxyethyl)morpholine, being stirred for 3 h, and being purified by silica gel column chromatography (CH2Cl2/EtOAc=1:4) to obtain the title compound (37%).
Aufarbeitung
- custombeing purified by silica gel column chromatography (CH2Cl2/EtOAc=1:4)
Quellen und Nachweise
- ORD-Eintrag
- ord-b483d7e2622f45bfb5f6653b099626a7
- Quelldatensatz
- uspto-grants-2014_11
- Patentnummer
- US08877747B2
Verknüpfte Notizen
Wird geladen…